Table 4.

Logistic regression analysis for risk factors associated with metastatic lymph nodes

Variables	Univariate			Multivariate
	HR	95% CI	p-value	HR	95% CI	p-value
SUVmax (≥4.6)	36.75	8.83–153.04	<0.000	5.45	0.47–062.73	0.174
CV (≥0.194)	25.14	7.13–088.64	<0.000	20.97	2.26–194.62	0.007
Size (≥6.8 mm)	04.71	1.67–013.32	0.003	1.30	0.07–022.60	0.859
Female gender	03.97	1.27–012.43	0.018	21.48	2.38–193.93	0.006
First line of treatment
Chemotherapy only	05.33	1.28–022.21	0.021	2.07	0.08–050.39	0.654
Location
Level II or retropharynx	06.96	2.26–021.49	0.001	8.89	1.10–071.74	0.04
Nodal staging (0, 1 vs 2, 3)	3.01	1.07–8.43	0.037	1.78	0.25–012.65	0.56
Prior history of recurrence	02.47	0.89–006.85	0.082
Stage (I vs)
II	00.83	0.11–006.11	0.858
III	01.83	0.30–011.26	0.513
IV	02.31	0.37–014.21	0.367
Histology (differentiated vs)
Non-keratinizing	01.56	0.33–007.36	0.577
Undifferentiated	01.29	0.34–004.90	0.713
Age (>50 years)	00.98	0.38–002.48	0.959
Loss of fatty hilum	1.20 × 109	0.00–00NC	0.999

CI, confidence interval; CV, coefficient of variation; HR, hazard ratio; NC, not calculable; SUV_max, maximum standardized uptake value.